DPP-4 inhibitors users exhibited a significantly reduced risk of HCC (aHRs: 0.53, 95% CIs: 0.44–0.65) after adjustment for age, sex, chronic hepatitis C virus infection, cirrhosis, anti-virus drug use, and insulin use (Table 3). Here, DPP4 is linked to chronic hepatitis C virus infection.